- A substantial proportion of multidrug-resistant (MDR) Salmonella bacteria is detectable in humans, according to a 2017-2018 ECDC and European Food Safety Authority (EFSA) report on data in humans, animals, and food.
- Findings highlight increases in high-level ciprofloxacin resistance in Salmonella isolates from 2016 (1.7%) to 2018 (4.6%).
Why this matters
- The increase in food-borne MDR Salmonella and other isolates highlights the need for enhanced surveillance, screening, and reporting.
- Clinicians should be vigilant for carbapenem-resistant infections.
- The report cites a high proportion of human Salmonella isolate resistance to:
- Sulfonamides (30.5%), tetracyclines (28.8%), and ampicillin (25.9%).
- 12.5% of Salmonella isolates were resistant to ciprofloxacin.
- Extremely high resistance was seen in S. Kentucky (85.7%), while the EU average was 29.6%.
- Sporadic cases of human carbapenem-resistant Salmonella infections were observed.
- Low rates of resistance to azithromycin (1.6%) and tigecycline (1.7%) were reported overall.
- Belgium had the highest rates of both: 4.7% azithromycin and 8.5% tigecycline.
- 51.5% of Salmonella spp. from broilers and 42.7% from turkeys were resistant to ciprofloxacin.
- 48.8% from broilers and 33.7% from turkeys were resistant to nalidixic acid.
- Escherichia coli susceptibility in food-producing animals increased in ~25% of member states from 2014 to 2018.